Endologix (ELGX) Misses Q1 EPS by 1c

Endologix (NASDAQ: ELGX) reported Q1 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $36.7 million versus the consensus estimate of $37.94 million.

John McDermott, Endologix Chairman and Chief Executive Officer, said, "During the first quarter we continued to drive adoption of both our EVAR and EVAS products for the treatment of AAA, led by strong performance from the Nellix® Endovascular Sealing System in Europe, where sales grew 32% year-over-year in constant currency. We also made good progress with our clinical and new product growth initiatives in the U.S., which we expect to provide a positive catalyst for growth in the second half of the year. Lastly, we filed the first module of the Nellix PMA in the first quarter and remain on track for potential FDA approval in late 2016."

For earnings history and earnings-related data on Endologix (ELGX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Cloudastructure reports 164% subscription revenue growth in Q2 2026
• BWS Financial Downgrades Inter Parfums (IPAR) to Sell